Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intravenous Iron in Gynecologic Cancer Patients Receiving Chemotherapy

This study has been completed.
Information provided by (Responsible Party):
Tarinee Manchana, Chulalongkorn University Identifier:
First received: September 14, 2011
Last updated: January 31, 2017
Last verified: January 2017
Can intravenous iron lower the rate of blood transfusion in gynecologic cancer patients receiving platinum based chemotherapy than oral iron?

Condition Intervention Phase
Gynecologic Cancer
Drug: Intravenous iron
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Prevention of Blood Transfusion With Intravenous Iron in Gynecologic Cancer Patients Receiving Platinum Based Chemotherapy

Resource links provided by NLM:

Further study details as provided by Chulalongkorn University:

Primary Outcome Measures:
  • Red blood cell (RBC) transfusion rate [ Time Frame: 6 months ]
    The requirement of red blood cell transfusion before administration of chemotherapy will be evaluated for 6 cycles of chemotherapy.

Secondary Outcome Measures:
  • total number of red blood transfusion units and number of cycles requiring blood transfusion [ Time Frame: 6 months ]
  • Number of participants with adverse events [ Time Frame: 6 months ]

Enrollment: 64
Study Start Date: June 2011
Study Completion Date: November 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intravenous iron
Iron sucrose 200 mg intravenous infusion in 15 minutes
Drug: Intravenous iron
Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
Other Name: Venofer
Placebo Comparator: Oral iron
Ferrous fumarate 200 mg oral three times a day
Drug: Intravenous iron
Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
Other Name: Venofer

Detailed Description:
Anemia is a common condition during chemotherapy administration. Treatment options usually include oral iron supplementation and blood transfusion. However, oral iron has gastrointestinal side effects, which affects patient compliance, and only a small amount of oral iron can be absorbed from the gastrointestinal tract. Intravenous iron may overcome a block of iron absorption and iron recycling induced by hepcidin. Therefore, it may increase hemoglobin level and reduced blood transfusion in cancer patients receiving chemotherapy.

Ages Eligible for Study:   20 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 20-70 years
  • Good performance status (Zubrod score < 2)
  • No serious underlying disease
  • Normal renal function test
  • Normal liver function test
  • Platinum based chemotherapy is the first line regimen
  • No prior or receiving radiotherapy

Exclusion Criteria:

  • Iron hypersensitivity
  • Underlying disease which has the risk of iron overload such as chronic kidney disease, major thalassemia
  • Progressive disease
  • Bone marrow metastasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01435200

Chulalongkorn Hospital
Bangkok, Thailand, 10330
Sponsors and Collaborators
Chulalongkorn University
Principal Investigator: Tarinee Manchana, MD Chulalongkorn University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Tarinee Manchana, Department of Obstetrics and Gynecology, Chulalongkorn University Identifier: NCT01435200     History of Changes
Other Study ID Numbers: IV iron 2
Study First Received: September 14, 2011
Last Updated: January 31, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Chulalongkorn University:
Intravenous iron
gynecologic cancer blood transfusion

Additional relevant MeSH terms:
Trace Elements
Growth Substances
Physiological Effects of Drugs processed this record on May 23, 2017